<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04099134</url>
  </required_header>
  <id_info>
    <org_study_id>PaCaReg</org_study_id>
    <nct_id>NCT04099134</nct_id>
  </id_info>
  <brief_title>PACAREG: a Multicenter Registry Trial in Pancreatic Ductal Adencarcinoma</brief_title>
  <acronym>PaCaReg</acronym>
  <official_title>PaCaReg: A Multicenter Registry Trial for the Assessement of Clinical, Epidemiological and Biological Profiles in Patients With Pancreatic Ductal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PaCaReg is a multicenter registry trial aiming in the assessement of clinical,
      epidemiological and biological profiles in patients with pancreatic ductal adenocarcinoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2018</start_date>
  <completion_date type="Anticipated">October 2029</completion_date>
  <primary_completion_date type="Anticipated">October 2028</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>General assessment of applied therapy modalities in pancreatic cancer</measure>
    <time_frame>First diagnose to death or end of surveillance (5 years after curative resection)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life in pancreatic cancer patients</measure>
    <time_frame>First diagnose to death or end of surveillance (5 years after curative resection)</time_frame>
    <description>EORTC QLQ c30 and PAN 26</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>General epidemiologic assessment</measure>
    <time_frame>First diagnose to death or end of surveillance (5 years after curative resection)</time_frame>
    <description>Epidemiologic questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tumor surveillance in pancreatic cancer patients</measure>
    <time_frame>First diagnose to death or end of surveillance (5 years after curative resection)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of predictive and prognostic markers</measure>
    <time_frame>First diagnose to death or end of surveillance (5 years after curative resection)</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Pancreas Adenocarcinoma</condition>
  <condition>Pancreas Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Tumor tissue from biopsies or surgery

        -  Blood samples at defined timepoints
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All adult newly diagnosed patients with a PDAC could be included in the registry trial.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment naive histologically or cytologically proven pancreatic ductal
             adenocarcinoma (PDAC) or highly suspicious diagnosis (only pre-curative-intended
             resection)

          -  Age =&gt;18 years

          -  written informed consent

        Exclusion Criteria:

          -  papillary cancer

          -  neuroendocrine pancreatic tumors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Seufferlein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ulm University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Seufferlein, MD</last_name>
    <phone>+49 731 50044501</phone>
    <email>thomas.seufferlein@uniklinik-ulm.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universit√§tsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Seufferlein, MD</last_name>
      <phone>0049-731-500-44501</phone>
      <email>thomas.seufferlein@uniklinik-ulm.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>September 23, 2019</last_update_submitted>
  <last_update_submitted_qc>September 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Thomas Seufferlein</investigator_full_name>
    <investigator_title>Head of department for internal medicine I</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

